TheraRadar
← Back
Data updated: Jun 28, 2026

Autolus, Inc.

Biotech
Pharmaceuticals Execution: Needs Improvement

Autolus, Inc. is a biotechnology company with 1 FDA-approved products.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Biologics

Autolus, Inc.'s Key Drugs

Autolus, Inc.'s core commercial portfolio centers on Aucatzyl — its most strategically important drugs approved in the last 15 years.

Aucatzyl
CD19 Approved 2024

Autolus, Inc.'s Recent FDA Approvals

Autolus, Inc. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

Aucatzyl BLA
2024-11-07
obecabtagene autoleucel
1 INDICATION AND USAGE AUCATZYL is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). AUCATZYL is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) ( 1 ).

Autolus, Inc.'s Therapeutic Areas

Disease areas where Autolus, Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

Autolus, Inc. Pipeline Snapshot

Active clinical trials for Autolus, Inc. across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Aucatzyl leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 55 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges